Adeno-associated virus (AAV) vectors with capsids of AAV serotype 9 enable an efficient transduction of the heart upon intravenous injection of adult mice but also transduce the liver. The aim of this study was to improve specificity of AAV9 vector-mediated cardiac gene transfer by microRNA (miR)-dependent control of transgene expression. We constructed plasmids and AAV vectors containing target sites (TSs) of liver-specific miR122, miR192 and miR148a in the 3¢ untranslated region (3¢UTR) of a luciferase expression cassette. Luciferase expression was efficiently suppressed in liver cell lines expressing high levels of the corresponding miRs, whereas luciferase expression was unaffected in cardiac myocytes. Intravenous injections of AAV9 vectors bearing three repeats of miR122 TS in the 3¢UTR of an enhanced green fluorescent expression (EGFP) expression cassette resulted in the absence of EGFP expression in the liver of adult mice, whereas the control vectors without miR TS displayed significant hepatic EGFP expression. EGFP expression levels in the heart, however, were comparable between miR122-regulated and control vectors. The liver-specific de-targeting in vivo using miR122 was even more efficient than transcriptional targeting with a cardiac cytomegalovirus (CMV)-enhanced myosin light chain (MLC) promoter. These data indicate that miR-regulated targeting is a powerful new tool to further improve cardiospecificity of AAV9 vectors.
INTRODUCTION
Heart diseases are one of the most important causes of death worldwide. Despite development of novel therapeutic modalities in the last decades, options for treatment of many heart diseases are still limited. Gene transfer to the myocardium has become a promising therapeutic strategy, as it allows highly specific modulation of singular genes or gene networks. Its suitability for employment in heart diseases has been demonstrated in several animal models of myocardial ischemia, 1 heart failure 2-4 and genetic disorders. 5 More recently, a first clinical trail for treatment of patients with advanced heart failure has been initiated. 6 As cardiac gene transfer efficiency of plasmid DNA is low even after local injection 7 viral vector systems have gained increasing interest. Among them the adeno-associated virus (AAV) vectors are currently the most potent and promising vectors used for delivery of transgenes to the heart. AAV vectors have several advantages over other viral vector systems as they are not associated with any disease in humans. Furthermore, they allow long-term gene transfer in humans. 8 Improvements in vector development resulted in so-called selfcomplementary (sc) AAV vectors harboring double-stranded genomes. 9 These vectors allow an extremely rapid and efficient expression of transgenes enabling even treatment of acute virus infections of the heart in a murine model. 10 Most importantly, identification of novel AAV serotypes 11 resulted in the development of AAV vectors suitable for an efficient cardiac gene transfer upon systemic application in mice as shown for AAV9. 3, 10, [12] [13] [14] [15] However, AAV9 vectors exhibit a broad tissue tropism and allow also transduction of the liver upon intravascular administration. 3, [12] [13] [14] 16, 17 Reduction of AAV-mediated transgene expression in the liver, however, may be a desirable aim to reduce unwanted side effects in cardiac gene therapy. Transcriptional control of gene expression is a promising approach to overcome this limitation. 18 A heterologous promoter containing the strong cytomegalovirus (CMV) enhancer and a cardiac myosin light chain (MLC)-2v promoter allowed an efficient and predominant gene transfer into the rodent heart, but could not completely prevent a low level hepatic gene expression. 19, 20 MicroRNAs (miRs) are a group of endogenous, short and non-coding RNA molecules that have a central role as key posttranscriptional regulators of gene activity including development, differentiation, apoptosis and proliferation. 21, 22 The molecules are transcribed by polymerase II as long hairpin precursor transcripts. After sequential processing steps, a double-stranded 18-24 nucleotide (nt) long miR is incorporated into the RNA-induced silencing complex. Only one strand (the guide strand) of the miR duplex remains stably associated with RNA-induced silencing complex and forms the mature miR, whereas the opposite strand is disposed. 23 By pairing with partially complementary sites in 3¢ untranslated regions (3¢UTRs) mature miRs mediate post-transcriptional silencing of genes. 24 Previous studies have demonstrated that the insertion of miR target sites (TSs) into the 3¢UTR of a gene expression cassette reduces expression levels of the transgene in cells and organs with high levels of corresponding miR expression. 25, 26 More recently, this approach was successfully introduced in gene therapeutic applications for prevention of oncolytic picornavirus-induced myositis 27 and to de-target replication deficient and oncolytic adenoviruses from the liver in vivo. [28] [29] [30] In this study, we analyzed the ability to restrict AAV9 vectormediated gene transfer to the heart through miR-mediated suppression of the transgene delivery in the liver. We show that cardiospecificity of AAV9 vectors can be drastically improved by insertion of three tandemly inserted TS with perfect complementarity to liver-specific miR122 into the 3¢UTR of a enhanced green fluorescent expression (EGFP) reporter gene expression cassette. Moreover, this approach was more efficient than a transcriptional targeting strategy using the cardiac CMV-MLC0.26 promoter.
RESULTS

Confirmation of liver tissue and liver cell-specific expression of miR122, miR192 and miR148a
Recently, miR array analysis has been shown that miR122, miR192 and miR148a are highly or abundantly expressed in the liver, whereas their expression is rare or absent in the heart, 31, 32 To verify these data, an in vivo expression profiling analysis was carried out, considering the levels of cognate miR expression in the liver and the heart. As shown in Figure 1a , miR122 showed the absolute highest expression levels in mouse liver, whereas miR192 and miR148a expression levels reached only 8.4 and 2.4% relative to miR122 expression levels. The expression of miR122 in the heart was drastically (about 53.000-fold) and the expression of miR192 moderately (about 71-fold) lower compared with the liver, whereas the expression of miR148a differed only slightly between heart and liver. Compared with miR122, however, the expression levels of miR192 and miR148a were 63-fold and 426-fold higher in the heart, respectively. Comparison of miR expression in liver cell lines demonstrated that human liver cell line Huh7 showed a similar miR expression profile as observed in mouse liver. AML12 mouse liver cells and more distinctly human HepG2 cells showed a different expression profile, with almost no expression of miR148a in AML12 and very low levels of miR122 in HepG2.
Furthermore, we determined miR122, miR192 and miR148a expression in primary human cardiac myocytes, in neonatal rat cardiac myocytes (NRCM) and in HL-1 cells, a cell line established from the murine atrium. miR122 and miR192 were actually rarely expressed in all cultured cardiac myocytes with up to 11.000-fold and 360-fold lower expression compared with miR122 expression determined in Huh7 cells. miR148a expression, however, was abundantly found in cardiac cells similar to the murine heart ( Figure 1b ).
De-targeting of transgene expression in liver cells by liver-specific miRs
To investigate whether vector-mediated transgene expression can be prevented by liver-specific miR, luciferase reporter gene expressing Comparison of liver-and heart-specific expression in vivo. Expression levels of miR192 and miR148a in mouse liver and miR122, miR192 and miR148a in mouse heart are shown as relatives to miR122 expression levels measured in the liver (¼100%). ***Po0.001 for each column versus control (first column). (b) Comparison of miR expression levels in liver cells and cardiac myocytes. Expression levels of miR122, miR192 and miR148a in the human liver cell lines Huh7 and HepG2, mouse liver cell lines AML12, permanent mouse cardiac cell line HL-1, NRCM and primary human cardiac myocytes (HCM) are shown as relatives to miR122 expression levels measured in Huh7 cells (¼100%, first white column in the left diagram, black column in the right diagram). miR expression profile in Huh7 cells was most similar to expression profile determined in mouse liver. All cardiac cells showed similar miR expression pattern as found in mouse heart. **Po0.01; ***Po0.001 for each column versus control (first column). Note: Although miR122 and miR192 are preserved among mouse, rat and human, miR148a sequence has been described for mouse and human but not for rat in the literature. However, a sequence complementary to mouse and human miR148a is located in the rat chromosome 4 and may represent the putative miR148a.
AAV vectors with microRNA target sites A Geisler et al plasmid vectors were constructed each containing a single TS with perfect complementarity to the mature miR122, miR192 and miR148a in the 3¢UTR of the expression cassette, respectively. Additionally, two constructs were produced containing either three or six tandem repeats of the miR122 TS, one construct that contains three tandem repeats of miR122 TS and three of miR192 TS, and one construct containing three tandem repeats of miR122 TS and one miR148a TS (Figures 2a and b) . Three different liver cell lines (Huh7, AML12 and HepG2), the cardiac cell line HL-1 and NRCM were transfected with these plasmids and the strength of miR-mediated suppression of luciferase reporter gene activity was determined. The extent of suppression of luciferase activity (Figures 3a and b) showed a clear correlation to the miR expression levels ( Figure 1b ) determined for each miR and cell line investigated. All tested constructs containing a single TS showed a reduction of luciferase activity in the investigated liver cell lines. An exception was seen for the miR148a TS construct, which was not suppressed in AML12 cells, which may be explained by lack of miR148a expression in this cell line (Figure 1b ). Highest suppression of luciferase expression with a reduction of about 81% for the miR122 TS construct was observed in Huh7 cells representing the cell line with absolutely highest miR122 expression. No significant change of luciferase activity was visible in NRCM. Only the construct carrying the miR148a TS resulted in distinctly suppressed reporter activities in HL-1 cells. An increase of miR TS repeats for miR122 TS from one (up to 81% reduction in Huh7) to three repeats (up to 92.2% reduction in Huh7) but also from three to six repeats (up to 94.8% reduction in Huh7) as well as combination of three miR122 TS repeats with three miR192 TS repeats (up to 94.6% reduction in Huh7 cells) significantly increased suppression of luciferase activity (Figure 3a ). This additive effect was only seen for miRs that were highly or moderately expressed in the corresponding cell line. In cardiac cells that express miR122 and miR192 at very low levels, these effects were negligible or absent (Figure 3b ).
miR-dependent regulation of AAV vectors
To verify plasmid data in the context of AAV vectors, we constructed three AAV6 pseudotyped vectors with sc vector genomes, bearing a luciferase reporter gene expression cassette with miR122 (3Â)TS , miR122 (6Â)TS and the combination of miR122 (3Â)TS /miR192 (3Â)TS . Corresponding to the results obtained after plasmid transfection, the luciferase expression was reduced up to 95% in Huh7 cells for all AAV constructs. A reduction of luciferase activity of about 90% for vectors containing the miR122 (3Â)TS /miR192 (3Â)TS was observed in AML12 cells. The luciferase expression in HL-1 and NRCM, however, was not affected (Figure 3c ).
miRs suppress luciferase expression by degradation of the TS-containing transcripts
In order to analyze whether miR-mediated inhibition of luciferase protein expression resulted from luciferase mRNA degradation or from inhibition of protein translation, we isolated total RNA from Huh7 cells transfected with miR122 TS, miR192 TS and miR148a TS-containing luciferase reporter plasmids, respectively and carried out northern blot hybridization to detect luciferase mRNA expression. The luciferase mRNA expression was distinctly decreased for all miR TS carrying constructs, indicating that regulation of reporter gene expression may preferentially occur through degradation of luciferase mRNA. Corresponding to the differences in miR expression levels measured in Huh7 cells, miR TS constructs containing multiple TS of miR122 or combination of miR122 (3Â)TS and miR192 (3Â)TS as well as single miR122 TS showed very strong suppression of luciferase mRNA expression, whereas expression of transcripts bearing single miR148a TS and miR192 TS was distinctly less suppressed ( Figure 4 ).
5¢ Deletion of miR122 TS abrogates miR122 suppression activity
Having shown that luciferase reporter expression regulated by liver-specific miRs is efficiently suppressed in liver cells, we were interested in identifying whether there are regions of the miR TS that are essential to ensure miR-mediated suppression. For this reason, we generated luciferase-expressing vectors bearing a single miR122 TS shortened stepwise at the 5¢ part to a total length of 21-7 nt. All miR122 TS variations, however, contained sequences complementary to the miR122 seed sequence. As shown in Figures 5a and b, luciferase expression was not suppressed for the constructs containing miR TS with 7-15 nt complementary to miR122, whereas strong suppression was visible for all miR TS with X17 nt. The strength of inhibition for the constructs with an miR TS length of 17-21 nt, were in the range of the suppression level of the original miR122 TS. In summary, these data demonstrate that the 3¢ part of miR122 TS including sequences complementary to the seed sequence of the miR122, the potential Argonaute 2 cleavage site (between the nt paired to bases 10 and 11 of the miR) and some nt upstream are essential for miR122-mediated silencing. Nevertheless, deletions of about one fourth of the miR122 TS on its 5¢ end are well tolerated and do not affect miR122-mediated silencing.
miR122-regulated AAV9 vectors efficiently de-target the liver without affecting the heart Encouraged by the in vitro data, we next analyzed whether regulation of transgene expression by liver-specific miRs can specifically suppress transgene expression in the liver following AAV vector-mediated gene transfer without affecting the heart in vivo. Therefore, we constructed two AAV9 vectors containing three tandem repeats of the miR122 TS in the 3¢UTR of an EGFP expression cassette. EGFP expression of the vector AAV9-CMV-EGFP miR122(3Â)TS was driven by a CMV promoter and EGFP expression of the vector AAV9-MLC0.26-EGFP miR122(3Â)TS was driven by the cardiac CMV-MLC0.26 promoter. Efficiency and specificity of these vectors were compared with corresponding vectors without miR TS (AAV9-CMV-EGFP and AAV9-CMV-MLC0.26-EGFP). Prior to generation of AAV vectors, we tested the respective AAV-shuttle plasmids in vitro in Huh7 and AML12 cells. As shown in Figure 6a , the miR122 TS-regulated constructs were strongly suppressed in Huh7 cells as expected and at less degree also in AML12 cells. Interestingly, EGFP expression was lower in case of the CMV promoter driven and miR122-regulated construct than in the CMV-MLC0.26 construct without miR TS. This suggests that miRdependent de-targeting may be more efficient than transcriptional targeting using the CMV-MLC0.26 promoter. The two miR122-regulated and two control AAV9 vectors were applied in each three animals per group at 7.5Â10 11 AAV9 vector genomes per animal via tail vein injection. After 4 weeks, mice were killed and tissue slices of the heart and liver were directly imaged for EGFP expression (Figure 6b ). There was a very strong EGFP expression in the heart of all animals transduced with AAV9 vectors harboring the CMV promoter irrespective of the presence or absence of miR122 TS. Similar expression levels were observed for AAV9 vectors containing the CMV-MLC0.26 promoter. No difference was observed in the cardiac transduction pattern between all groups (Supplementary Figure 1) . In skeletal muscle, expression levels were close to background in all groups (Supplementary Figure 2) . In the liver, all three animals transduced with AAV9-CMV-EGFP and two of three animals transduced with AAV9-CMV-MLC0.26-EGFP showed markedly EGFP expression. However, EGFP expression was distinctly lower for the CMV-MLC0.26 promoter compared with the CMV promoter driven constructs. In sharp contrast, hepatic EGFP expression was completely absent in all animals transduced either with AAV9-CMV-EGFP miR122(3Â)TS or AAV9-CMV-MLC0.26-EGFP miR122(3Â)TS (Figures 6b and c) . To exclude that differences in EGFP expression resulted from differences in transduction efficiency of distinct AAV vectors, the amount of vector DNA in the liver and the heart was determined and found to be similar (Supplementary Figure 3) . This supports that liver-specific suppression of EGFP expression in the miR122 TS-containing AAV vectors did not result from lower liver transduction of the respective vector batches. These data clearly demonstrate that AAV9 vector-mediated transgene expression can efficiently be suppressed in the liver by insertion of miR122 TS into AAV9 vector genomes. Most importantly, abolishing transgene expression in the liver occurred without affecting the transgene expression in the heart. Moreover, our data indicate that de-targeting of the liver by miR122 regulation was even more efficient than utilization of a cardiac promoter.
Absence of side effects after miR122-regulated AAV vector transduction in vivo Exclusion of side effects following vector transduction is a major intention of gene therapy. To exclude possible side effects, we analyzed histological sections of liver tissue of mice transduced with AAV9-CMV-EGFP miR122(3Â)TS and AAV9-CMV-MLC0.26-EGFP miR122(3Â)TS vectors. Additionally, expression of endogenous miR122 levels and expression of Gys1, representing a protein that is potentially regulated by miR122, 33 were determined. Liver sections did not reveal any signs of necrosis or inflammation (Figure 6d ). In fact, no differences were seen in comparison to liver sections of wild-type mice. Moreover, miR122 expression profile did not differ to the wild-type mice ( Figure 6e ) and Gys1 expression was not changed (Figure 6f ), indicating that miR122 was not saturated by miR122 TS expressed by AAV9 vectors. In summary, these data reveal the absence of any side effects or dysregulations of genes that represent potential targets of miR122 after transduction of the liver with miR122 TS bearing AAV9 vectors.
DISCUSSION
Cardiac-specific delivery of a transgene is an important prerequisite for gene therapy of cardiac diseases especially if the transduction of extracardiac tissue may be a potential risk of side effects. A breakthrough in cardiac gene transfer was achieved with the finding that AAV vectors based on AAV serotypes 6 and 9 allow an efficient cardiac transduction in rodents. 3, 10, [12] [13] [14] [15] 34 By selection of an AAV cap gene library generated by DNA shuffling of different AAV serotype capsid genes, a novel AAV vector (AAVM41) was identified whose capsid is composed by elements of AAV1, 6, 7 and 8. This vector revealed a similar transgene expression efficiency in murine myocardium as AAV9 but significantly reduced gene transfer into the liver. 17 Transcriptional targeting with cardiac-specific promoters has been described as another valuable strategy to improve specificity of cardiac transgene delivery. We could recently show that expression of a transgene driven by a CMV-MLC1.5-hybrid promoter is suitable to increase specificity of cardiac transgene expression of AAV vectors. 19 However, despite significant improvements by employment of cardiotropic AAV vectors and use of heart-specific promoters residual expression of transgenes stayed still detectable in several non-targeted tissues following AAV vector application. 19 miR-dependent regulation has recently emerged as a powerful new tool to improve specificity of transgene delivery 25 and has been used in gene therapy approaches with lentiviral 35 and adenoviral vectors 28, 29, 36 as well as oncolytic picornaviruses. 27 In a proof of concept approach we have aimed to investigate the potential of this technique to improve the specificity of AAV vectors to the heart by de-targeting AAV9 vectors from the liver. Initial evaluation of three miR candidates (miR122, miR192 and miR148a) that have recently been described to be selectively expressed in the liver 31, 32 confirmed that miR122 was most abundantly and selectively expressed in murine liver. Regulation of AAV9 vector-mediated expression by miR122 in the heart and the liver in vivo. Each three mice per group were injected with 7.5Â10 11 vg of AAV9-CMV-EGFP, AAV9-CMV-EGFP miR122(3Â)TS, AAV9-CMV-MLC0.26-EGFP and AAV9-CMV-MLC0.26-EGFP miR122(3Â)TS via tail vein injection. After 4 weeks, animals were killed and organs were dissected and rapidly frozen in liquid nitrogen. In all, 10 mm cryosections of heart and liver were evaluated for EGFP expression by fluorescence microscopy using direct imaging of tissue slices. Representative microphotographs are shown for heart (upper row overview, lower row magnification) and liver. EGFP expression in the heart was similar in mice having received vectors with the CMV promoter compared with the CMV-MLC0.26 promoter. Cardiac EGFP expression was similar between miR122 TS-regulated vectors and corresponding control vectors. Both AAV9 control vectors containing the CMV-MLC0. 26 and CMV promoter without miR122 TS sequences showed EGFP expression in the liver, whereas both miR122-regulated AAV9 vectors did not show any EGFP expression in the liver. Bar heart and liver: upper row 500 mm, lower row 100 mm. Nevertheless, also miR192 showed high and liver specific expression, whereas only low levels in the liver and no cardiac specificity were found for miR148a. In vitro analysis revealed that among tested liver cell lines only Huh7, but all cardiac myocyte cell lines reflected the in vivo expression pattern of these three miRs. Based on these data, we considered miR122 as the most suitable potential regulator molecule for AAV vectors.
Carrying out a step-by-step analysis of functional mechanisms of miR-dependent regulation of reporter transgene expression in vitro confirmed this hypothesis. Moreover, our results exhibit several findings with general and specific impact for utilization of miRdependent regulation of AAV vectors. Our data reveal that expression levels of all three investigated miRs inversely correlated with their suppression activity. On the first view, this seems to be obvious as an increase of miR concentration per cell might result in a higher probability to bind to a corresponding miR TS, resulting in increased suppression of the transgene. 37 Others, however, have described some miR that obviously do not follow this relationship and suppress the 
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heart liver targets independently from their expression levels. 25 The mechanism is currently not completely understood, but factors that directly or indirectly influence the miR or the cell may be involved therein. 38, 39 Nevertheless, miR122 TS-regulated reporter followed a clear relationship between expression levels and suppression activity. Interestingly, efficient suppression was not only observed when the miR122 TS perfect complementary to mature miR122 was used in the constructs, but also when 5¢ deleted miR122 TS variants with 17-21 bp length were used. Moreover, a simple nt substitution from G to T immediately following the 3¢ end of the miR122 TS significantly influenced miR122 suppression activity of the 20 nt miR122 TS construct (results not shown). This demonstrates on the one hand that the 5¢ part of the miR122 TS is not required for miR122-mediated silencing. On the other hand, it suggests that structural events outside the miR TS might not obligatory be connected with miR122 binding to its TS but still influence silencing.
In agreement with earlier reports, 25, 40, 41 our data confirm that the number of repetitive miR TS can aggravate miR-mediated suppression of the transgene expression. We observed that the degree of suppression measured for constructs with three miR122 TS repeats was markedly increased to about 92% compared with constructs bearing only a single miR TS, which results only in a reduction of about 81% in Huh7 cells. This could be explained by serial binding of miR to the target mRNA that subsequently may result in increased cleavage events after introduction of the miR-mRNA complex into the miR silencing pathway. Nevertheless, a simple additional steric inhibition by forming stable miR-miR TS duplexes has also been taken into account. The concatamerization of miR122 TS to six tandem repeats resulted in a significant but only negligible further improvement of suppression in vitro when compared with constructs carrying three elements. This observation is in line with a report showing that 12 copies of miR122 TS did not further improve suppression activity of an oncolytic adenovirus vector compared with the vector containing six copies of the miR122 TS. 28 In general, it seems that already three to six copies of the miR TS are sufficient to achieve maximal suppression by a highly expressed miR. It is important to note that also the combination of miR122 TS and miR192 TS acted in an additive manner and increased suppression of gene expression after transfer of vectors in liver cell lines in vitro. However, an advantage of this combination over utilization of miR122 TS alone was only seen in cells with comparable high or moderate expression levels of the corresponding miR. In Huh7 cells, AAV6 vectors bearing miR122 TS/miR192 TS with each three TS repeats did not result in higher reporter gene suppression than AAV6 with only three repeats of miR122 TS. For this reason, we did not choose this combination variant for our in vivo applications. In other application as for example control of viral replication, a combination of different miR TS may have an advantage, as it might help to prevent occurrence of escape mutants emerged from mutation in one miR TS. 27 Importantly, both expression of concatamerized miR122 TS and combination of miR122 TS and miR192 TS from AAV6 vectors in vitro did not affect the transgene expression in cardiac cells. This in fact underlines the specificity of the liver-specific miR approach in vitro.
In previous studies, we have used cardiotropic AAV9 vectors 3,10,20 and cardiac-specific promoters in combination with AAV vectors 19 with the intention to improve specificity of cardiac transgene delivery in vivo. Although this approach resulted in a markedly increase in cardiac specificity, some transgene expression could still be detected in the liver of transduced animals. In the present study, we could show that EGFP reporter expression of AAV9 vectors bearing three miR122 TS were completely abolished within the liver, whereas expression was unaffected in the heart. This was observed irrespective of whether EGFP was driven by a CMV or cardiac CMV-MLC0.26 promoter. It demonstrates that regulation by miR122 is an efficient method to de-target AAV vectors from the liver in vivo and confirms that three miR122 TS inserted into the AAV9 vector genome are sufficient to achieve this aim. Moreover, according to a recent study, 28 the lack of any EGFP expression in the liver indicates that miR122-mediated suppression in vivo is much stronger than in vitro. Most likely, this discrepancy may result from several fold higher miR122 expression in primary hepatocytes in vivo compared with Huh7 cells. 28 Importantly, miR122-dependent hepatic de-targeting of AAV9 vectors seems to be per se superior to transcriptional targeting of the vector to myocardium using the cardiac CMV-MLC0.26 promoter. These findings may now open a novel way to increase specificity of AAV-mediated transgene delivery to the heart and other organs. Especially in cases when no tissue-specific promoter is available, its activity is too low to induce expression at sufficient levels or it is only necessary to protect few selected organs from the transgene, miRdependent AAV vector regulation may be employable. Furthermore, it was shown that tissue-specific promoters and miR act in an additive manner leading to improvement of vector specificity. 28 Although direct detection of EGFP on histological sections in our study was too insensitive to reveal such possible additive effects, a similar effect might occur.
We observed no hepatic side effects in vivo by application of AAV vectors harboring miR122 TS underlining the safety of our approach. In this regard, it should be noted that several vectors bearing miR TS have successfully been used as competitive inhibitors to repress miRs. Repression of miR by corresponding miR TS is possible, but only when the miR TS are expressed from a strong promoter at very high levels and/or the transgene contains multiple tandem miR TS (X6), which preferentially contain a bulge at position 9-12 to prevent RNA interference type endonucleolytic cleavage of the miR-miR TS duplex by Argonaute 2. 26, 42, 43 None of these features are characteristics of the miR-regulated AAV vectors used here. Therefore, AAV vectors with miR122 TS are obviously unable to deregulate endogenous miR122 expression levels and induce side effects.
Finally, based on its small genome size, AAV vectors have a comparable low packaging capacity for foreign DNA. This, however, may not limit the utilization of miR TS concatamers to control transgene expression. In general, miR TS have sizes below 100 bp. Several different miR TS regulator units may be inserted into a single AAV vector genome without oversizing the genome, even when AAV vectors with sc genomes are generated. Therefore, miR mediating de-targeting seems to be ideal for improving specificity of AAV vector-mediated transgene expression.
In summary, our proof of concept study demonstrates that miR122 TS bearing cardiotropic AAV9 vectors can efficiently de-target gene expression from the liver. Because of its efficiency, specificity, absence of side effects, and high homology between different species, miR-dependent regulation techniques have the potential to be used in the context of AAV vectors in a wide panel of applications.
MATERIALS AND METHODS
Cell cultures
Huh7 cells (kindly provided by Christian Freise, Department of Gastroenterology, Infectiology and Rheumatology, Charité, Berlin, Germany) and HepG2 cells (both representing human hepatocellular cell lines) as well as 293 (human embryonal kidney) cells were cultured in high glucose Dulbecco's Modified Eagle's Medium (Invitrogen GmbH, Karlsruhe, Germany). AML12, a mouse liver immortalized cell line (kindly provided from Anna Foryst-Ludwig, Center for Cardiovascular Research, Charité, Berlin, Germany) was cultured in high glucose Dulbecco's Modified Eagle's Medium/Ham's F12 with glutamine (Sigma-Aldrich Chemie, Steinheim, Germany) supplemented with 0.005 mg ml À1 insulin, 0.005 mg ml À1 transferrin, 5 ng ml À1 selenium (Sigma-Aldrich) and 40 ng ml À1 dexamethasone (Sigma-Aldrich). Media of permanent cell lines Huh7, HepG2, 293, AML12 were supplemented with 10% fetal calf serum and 1% of each penicillin and streptomycin. The HL-1 cell line, a cardiac muscle cell line established from an AT-1 mouse atrial cardiomyocyte tumor lineage, was a kind gift from William C Claycomb (LSU Health Center, New Orleans, LA, USA). The cells were maintained in Claycomb medium (SAFC Biosiences, Lanexa, KS, USA) supplemented with 10% fetal calf serum, 1% of each penicillin and streptomycin, 0.1 mM norepinephrine (SigmaAldrich) and 2 mM L-glutamine (Invitrogen). Before culturing HL-1 cells, tissue culture flasks were coated with fibronectin/0.02% gelatine (Sigma-Aldrich). Primary NRCM were isolated from neonatal rats and cultured in CMRL 1415 Medium (Biochrom, Berlin, Germany) supplemented with 2.8 mM glucose, 5.4 mM KCl, 1.26 mM CaCl 2 , 2 mM 5¢ fluoro-2¢-deoxyuridine (Sigma-Aldrich), 10% fetal calf serum and 2 mg ml À1 of gentamycin (Biochrom) as described. 44 Human cardiac myocytes from normal human ventricle tissue of the adult heart (PromoCell, Heidelberg, Germany) were cultured in myocyte growth medium (PromoCell) supplemented with SupplementMix (PromoCell).
Plasmid construction
To generate AAV-shuttle plasmids containing miR TS, a DNA fragment containing three repeats of miR122 TS and one of miR148a TS (5¢-tct aga tcg cga aca aac acc att gtc aca ctc cag tat aca caa aca cca ttg tca cac tcc aga tat cac aaa cac cat tgt cac act cca agg cct aca aag ttc tgt agt gca ctg agt tta act cta ga-3¢) was synthesized, inserted into pBluescript II SK (+) (ATG:biosynthetics, Merzhausen, Germany), and amplified from the plasmid with primers M13 Forward and M13 Reverse (Invitrogen). The fragment was inserted into a single XbaI site at the 3¢UTR of luciferase expression cassette of AAV-shuttle plasmid pUF-CMV enh /MLC0.26-Luc containing a cardiac (CMV)-enhanced 0.26 kb rat MLC promoter (MLC0.26) driving a luciferase reporter gene. The resulting plasmid was termed pUF-Luc miR122(3Â)TS/miR148a(1Â)TS . To exchange the miR148a TS by the miR192 TS, oligonucleotides 5¢-cct ggc tgt caa ttc ata ggt ca gt-3¢ and 5¢-cta gac tgac cta tga att gac agc cag g-3¢ were annealed and ligated into StuI and XbaI digested pUF-Luc miR122(3Â)TS/miR148a(1Â)TS resulting in pUF-Luc miR122(3Â)TS/miR192(1Â)TS . Plasmids containing single miR122 (pUF-Luc miR122(1Â)TS ), miR148a (pUF-Luc miR148a(1Â)TS ) or miR192 (pUFLuc miR192(1Â)TS ) TS as well as a triplet of the miR122 TS (pUFLuc miR122(3Â)TS ) were derived from pUF-Luc miR122(3Â)TS/miR148a(1Â)TS and pUF-Luc miR122(3Â)TS/miR192(1Â)TS . Plasmids containing tandems of three miR122 TS and three miR192 TS (pUF-Luc miR122(3Â)TS/miR192(3Â)TS ) and six miR122 TS (pUF-Luc miR122(6Â)TS ) were generated by inserting two additional miR192 TS into the plasmid pUF-Luc miR122(3Â)TS/192(1Â)TS and three miR122 TS into the plasmid pUF-Luc miR122(3Â)TS , respectively. pUFLuc miR122(1Â)TS plasmids with a single miR122 TS having homology to miR122 fragments ranging from 7 to 21 nt were generated by insertion of appropriate DNA fragments obtained by oligonucleotide annealing into the 3¢UTR of pUF-CMV enh /MLC0.26-Luc via a single XbaI site. Two AAV vector-shuttle plasmids with sc vector genomes containing an enhanced green fluorescent protein (EGFP) reporter gene under control of either the CMV or the CMV-MLC0.26 promoter were generated by insertion of a DNA fragment containing three repeats of miR122 TS into the BsrGI site of the 3¢UTR of the EGFP expression cassette in the plasmids pscAAV-CMV-EGFP 20 and pscAAV-CMV-MLC0.26-EGFP 20 resulting in pscAAV-CMV-EGFP miR122(3Â)TS and pscAAV-CMV-MLC0.26-EGFP miR122(3Â)TS , respectively. Plasmids were controlled by sequence analysis using an ABI 310 Genetic Analyzer (Applied Biosystems Inc., Forster City, CA, USA).
Generation of AAV vectors
AAV6 pseudotyped vectors were generated by co-transfection of 293 cells with the respective AAV-shuttle plasmid containing a luciferase reporter gene expression cassette and the AAV packaging plasmid pDP6-rs providing the AAV2 rep and AAV6 cap genes and adenoviral helper functions. AAV9 pseudotyped vectors were generated by co-transfection of AAV-shuttle plasmids containing an enhanced EGFP expression cassette with the plasmids p5E18-VD2/9 45 providing AAV2 rep and AAV9 cap genes as well as pDGdelVP 46 providing the adenoviral helper sequences. All AAV-shuttle plasmids contain AAV2-ITRs flanking the AAV vector genome at its 5¢ and 3¢ end. AAV-shuttle plasmids packaged into AAV9 pseudotyped vectors provide an sc vector genome, whereas AAV-shuttle plasmids packaged into AAV6 pseudotyped vectors provide a monomeric vector genome because the Firefly luciferase cDNA is too big in size to become packaged into sc vectors. Generation of AAV6 and AAV9 vectors was carried out as described previously 10 with some variations. Briefly, for AAV6 production, 293 cells were seeded to 14.5 cm (10 plates were used for preparation of each AAV vector) and transfected at next day at a confluence of about 70%. For transfection of one plate 61.92 mg Polyethylenimine (Polysciences Inc., Warrington, PA, USA) was diluted in 1 ml of 150 mM NaCl and 6 mg AAV-shuttle plasmid and 18 mg of pDP6-rs were diluted in 1 ml of 150 mM NaCl. Polyethylenimine solution was then added dropwise to the plasmid solution and incubated at room temperature for 15 min. The transfection mixture was added dropwise to the plate, and cells were incubated at 37 1C. After an incubation period of 72 h, cells were harvested and the cell supernatant was collected. Cells were pelleted by centrifugation at 3000 r.p.m. in a centrifuge 5810 R (Eppendorf, Hamburg, Germany), than washed three times with phosphate-buffered saline and resuspended in phosphate-buffered saline. After three freeze-thaw cycles, Benzonase (Merk KGaA, Darmstadt, Germany; final concentration of 250 U ml À1 ) was added, and the lysates were incubated for 1 h at 37 1C. Cell debris was pelleted and supernatant stored at À80 1C.
The cell supernatant (20 ml) of one plate was mixed with 0.4 ml of 2.5 mM CaCl 2 and incubated on ice for 1 h. After centrifugation at 4000 r.p.m. for 30 min, 6.5 ml of 24% PEG/NaCl (1.86 M) solution was added to the supernatant and incubated at 4 1C for at least 24 h and centrifuged again. Pellets were resuspended in a buffer containing 50 mM Hepes, 150 mM NaCl, 25 mM EDTA and centrifuged at 8000 r.p.m. for 30 min. The supernatant was incubated with Benzonase (final concentration 250 U ml À1 ) for 1h at 37 1C and stored at À80 1C. Vector solutions from the cell pellets and supernatant were pooled and vectors were purified using Iodixanol step gradients. 47 AAV9 vectors were produced and purified as described previously. 19, 20 Purification of virus was carried out by a filtration cascade followed by an iodixanol step gradient centrifugation. 19, 20 Vector titers were determined by quantitative real-time PCR using the primers 5¢-tgc cca gta cat gac ctt atg g-3¢ and 5¢-gaa atc ccc gtg agt caa acc-3¢ and the 6-fam-agt cat cgc tat tac cat gg-MGB-labeled probe directed against a target sequence located in the CMV promoter enhancer present in all AAV vectors genomes by use of the StepOnePlus Realtime PCR System (Applied Biosystems Inc.). 
Plasmid transfection
In vitro gene transfer
Cells seeded in 24-well plates were incubated with serum-free medium containing 2Â10 3 AAV6 vector genome equivalents per cell. After 2 h, medium was replaced by culture medium, and cells were further incubated. Because of low transduction efficiency of AML12 cells, vector incubation time was extended to 12 h. Reporter gene expression was analyzed 48 h after transduction.
Quantitation of luciferase expression
Firefly luciferase activity of the AAV reporter vectors was measured using the Luciferase Reporter Gene Assay (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer's instructions. In cells co-transfected with Firefly and Renilla luciferase-expressing plasmids, the luciferase activity was determined with the Dual-Luciferase Reporter Assay (Promega GmbH, Mannheim, Germany). Luciferase activity was measured in a Lumat LB 9501 luminometer (Berthold Technologies, Bad Wildbad, Germany).
Quantitation of AAV vector DNA
Genomic DNA was extracted from heart and liver tissue using the DNeasy tissue kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations. AAV vector DNA was quantified by real-time PCR using the TaqMan Gene Expression Master Mix (Applied Biosystems Inc.) and oligonucleotide primers/probe as follows: EGFP forward primer 5¢-acg taa acg gcc aca agt tc-3¢, EGFP reverse primer 5¢-aag tcg tgc tgc ttc atg tg-3¢ and EGFP probe 6fam-cga ggg cga tgc cac cta cg-TAMRA. Data were normalized to the genomic DNA (TaqMan Gene Expression Assay mGAPDH_g1). PCR reactions were carried out in triplicate with the StepOnePlus Realtime PCR System (Applied Biosystems Inc.).
Analysis of endogenous miR and gene expression
miR-enriched total RNA was isolated from cultured cells or tissues with mirVana miRNA Isolation Kit according to the recommendation of the supplier (Applied Biosystems Inc./Ambion, Austin, TX, USA). In all, 50 ng of isolated RNA was reverse transcribed using miR122, miR192 and miR148a specific primers (TaqMan MicroRNA Reverse Transcription Kit, Applied Biosystems Inc.). Expression levels were determined by real-time PCR (TaqMan MicroRNA Assays hsa-miR122, hsa-miR192, hsa-miR148a, Applied Biosystems Inc.). For normalization, U6snRNA expression was used (Applied Biosystems Inc.). To analyze Gys1 expression in the liver, 2 mg of RNA was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems Inc.). Expression levels were determined by real-time PCR (TaqMan Gene Expression Assay mouse Gys1, Applied Biosystems Inc.). Mouse HPRT expression was used for normalization (TaqMan Gene Expression Assay mHPRT1, Applied Biosystems Inc.). PCR reactions were carried out in triplicate with the StepOnePlus Realtime PCR System (Applied Biosystems Inc.).
Northern blot hybridization
Total RNA was isolated with mirVana miRNA Isolation Kit (Applied Biosystems Inc./Ambion) following the manufacturer's instruction. In all, 10 mg of isolated RNA was electrophoretically separated on a 1% formaldehyde agarose gel. After transfer to a Hybond N nylon transfer membrane (GE Healthcare, Buckinghamshire, UK), the membranes were hybridized with a single-stranded antisense Firefly luciferase-specific DNA probe, which was amplified with Luc-sense (5¢-ccg gcg cca ttc tat cc-3¢) and Luc-antisense (5¢-cga gaa tct gac gca gg-3¢) and labeled with 32 P-dCTP in a PCR-like reaction 48 using the Luc-antisense primer. Loading of equal amounts of RNA was verified by rehybridization with a single-stranded antisense b-actin-specific DNA probe as previously described. 49 Hybridized filters were exposed to Kodak BioMax MR film (Sigma-Aldrich).
In vivo gene transfer
All procedures involving the use and care of animals were performed according to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and the German animal protection code. Approval was also granted by the local ethics review board.
In all, 7.5Â10 11 vector genome equivalents of AAV9 vectors were intravenously injected into the tail vein of 2-month-old NMRI mice (Charles River Laboratories, Sulzfeld, Germany) as 150 ml bolus using a sterile syringe and 29-gauge needle. After 4 weeks, animals were euthanized by cervical dislocation. Organs were dissected and rapidly frozen in liquid nitrogen. For histological analyses, tissue was embedded individually in tissue freezing medium (Jung, Nussloch, Germany) and frozen in liquid nitrogen.
Histological and fluorescence analysis
To analyze EGFP reporter gene activity within mouse heart and liver, 10 mm cross-sections of fixed and cryoconserved tissue were performed (CM3050S; Leica, Wetzlar, Germany) and evaluated for EGFP expression (FITC, 515-555 nm) in combination with Dapi staining by fluorescence microscopy (Nikon Eclipse 90i upright automated microscope, Düsseldorf, Germany) using the D1QM camera (Nikon). Optical overview images were obtained by the 'scan large image' function of the microscope. To rule out relevant inflammation, 6 mm cryoslices were stained with hematoxylin/eosin. The tissue was evaluated by transmission microscopy (digital microscopy research biology (DMRBE); Leica) using the 3CCD-XC-003P color-camera (Nikon). To determine EGFP expression of AAV-shuttle plasmids, in vitro images of EGFPexpressing cells were taken 48 h after transfection by fluorescence microscopy (microscope Axio Observer.D1; Carl Zeiss AG, Jena, Germany) using the AxioCam camera MRc and Axiovision Rel. 4.7 software (Carl Zeiss AG). Counting of EGFP-expressing cells in microphotographs was carried out using the software 'Image J' (http://rsbweb.nih.gov/ij/) with the function 'analyze particles' . In each mouse, three different sections per organ were analyzed followed by calculation of the mean and standard error of mean (s.e.m.).
Statistical analysis
All data were expressed as mean ± standard error of mean (s.e.m.). To test for statistical significance, an unpaired Student's t-test was applied.
